![Clinical Thyroidology for the Public](https://www.thyroid.org/wp-content/uploads/2020/03/ctfp.png)
From Clinical Thyroidology® for the Public: Most children with thyroid cancer do very well as…
From Clinical Thyroidology® for the Public: Most children with thyroid cancer do very well as…
From Clinical Thyroidology® for the Public: A small fraction of people who have thyroid surgery…
Thyroid Cancer Survivorship: A Physician’s Own Experience Kaniksha Desai, MD, interviews Anupam Kotwal, MD, about…
From Clinical Thyroidology® for the Public: Once a cancer is diagnosed and surgery is an…
Given the evolving landscape of therapeutic options for RAIR-DTC, it is essential to highlight the importance of timely evaluating patients with advanced thyroid cancer.
Thyroid cancers (TC) are driven by a handful of genetic alterations. Papillary TC primarily harbors mutations involving BRAF, RAS or RET genes.
Medullary thyroid cancer (MTC) is a rare thyroid malignancy and considered a neuroendocrine type of tumor.
There are limited number of studies that have examined patients preferences concerning treatment options for patients with thyroid cancer.
Thyroid cancer in pediatric patients is not a rare entity, in fact it is the most common non-CNS solid tumor in childhood.
Familial non-medullary thyroid cancer (FNMTC) constitutes 3–9% of all thyroid cancer cases and is divided into syndromic and non-syndromic FNMTC.